-
Mashup Score: 5
Enrique Grande, MD, PhD, MD Anderson Cancer Centre Madrid, Madrid, Spain, discusses the implications of the findings from the EV-302 trial (NCT04223856) of enfortumab vedotin, an antibody-drug conjugate (ADC), and pembrolizumab in patients with locally advanced or metastatic urothelial cancer. The investigational regimen was found to be superior to the current standard of care, which typically consists of a cisplatin or carboplatin-based therapy in terms of medial overall survival. Consequently, enfortumab vedotin and pembrolizumab is seen as practice-changing. This interview took place at the European Society for Medical Oncology (ESMO) Asia 2023 Congress in Singapore. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjoncology.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 3Colonoscopy: primary screening with evolving challenges - 13 day(s) ago
Aasma Shauka, MD, MPH, New York University, New York, NY, discusses the current landscape of colonoscopy screening in the United States. Colonoscopy is the primary screening modality due to its ability to detect both large lesions and small adenomas that can be removed during the procedure, preventing future cancer. The advantage of an infrequent interval of ten years after a negative colonoscopy is highlighted. However, Dr Shaukat acknowledges the invasive nature and resource-heavy aspects of colonoscopy, leading to barriers for some patients. While colonoscopy is expected to remain the primary screening modality, non-invasive tests may help reach individuals currently not undergoing screening. This interview took place at the 2024 ASCO Gastrointestinal (GI) Cancers Symposium in San Francisco, CA. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjoncology.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1
Christoffer Gebhardt, MD, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, summarizes the emerging immunotherapeutic treatment landscape for patients with melanoma. The ongoing Phase III INTerpath-001 trial (NCT05933577) employs a combinatory therapeutic approach, using individualized neoantigen therapies (INTs) and pembrolizumab. Rather than using pembrolizumab alone, this immunotherapeutic combination has been evidenced in prior trial data as highly effective, lowering the hazard ratio for distant metastasis free survival. This interview took place at the 2024 American Association for Cancer Research (AACR) in San Diego, CA. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjoncology.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2Assessing operability in NSCLC: challenges and considerations - 16 day(s) ago
Mariana Brandao, MD, PhD, Institute Jules Bordet, Brussels, Belgium, delves into the complexities of defining operability in non-small cell lung cancer (NSCLC), acknowledging the unique challenges posed by the necessity of the lungs for survival. She outlines three key factors in assessing operability: oncological operability, focusing on the potential for surgery to improve cure rates compared to other treatments; functional operability, which involves evaluating patient comorbidities and assessing cardiac and pulmonary function to determine surgical tolerance; and technical operability, based on anatomical criteria such as tumor size, location, and relation to adjacent structures, aiming for clear pathological margins. Dr Brandao emphasizes the challenges posed by stage three disease, characterized by heterogeneous tumor characteristics and varying degrees of lymph node involvement, which can complicate surgical decision-making. This interview took place at the BTOG 2024 congress in
Source: www.vjoncology.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1Lung cancer initiation: towards molecular cancer prevention - 17 day(s) ago
Charles Swanton, Francis Crick Institute in London, discusses his research on the initiation and progression of lung cancer in response to air pollution exposure. Focusing on non-small cell lung cancer (NSCLC) in never smokers, Prof. Swanton presents findings from mouse models and human epidemiology datasets, revealing a link between air pollution and increased tumor formation. He proposes that air pollutants trigger an inflammatory response mediated by macrophages, leading to the transformation of preexisting lung stem cells into tumors. Prof. Swanton explores the role of myeloid cells in cancer initiation and progression, highlighting the significance of clonal hematopoiesis of indeterminate potential (CHIP). This interview took place at the BTOG 2024 congress in Belfast, UK. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjoncology.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0VJOncology – The video journal of oncology - 18 day(s) ago
The Video Journal of Oncology (VJOncology) is an independent, global, open-access video journal, dedicated to providing trusted and up-to-date information in order to improve the awareness and understanding of oncology
Source: www.vjoncology.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2CHRYSALIS: amivantamab in wild-type, pre-treated NSCLC - 20 day(s) ago
Natasha Leighl, MD, University of Toronto, Toronto, Canada, discusses findings from the Phase Ib CHRYSALIS trial (NCT02609776) of amivantamab, an EGFR-MET bispecific antibody, in patients with wild-type non-small cell lung cancer (NSCLC) who have progressed on checkpoint inhibition and chemotherapy. Two cohorts consisting of patients with either adenocarcinomas or squamous lung cancer were recruited, and responses were reported in both cohorts, but patients with KRAS or HER2 mutations did not respond to therapy. This interview took place at American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, CA. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjoncology.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1
Tatsuhiro Shibata, PhD, University of Tokyo, Tokyo, Japan, comments on emerging biomolecular therapeutic targets for the treatment of patients with gastric and gastroesophageal cancers. Promising biomarker targets include epidermal growth factor receptor 2 (EGFR2), claudins, and ones for immune checkpoint inhibitors (ICI). Prof. Shibata emphasizes that his session is being delivered at an opportune time, given the current state of scientific research on potential treatments for gastroesophageal cancer. This interview took place at the 2024 American Association for Cancer Research (AACR) in San Diego, CA. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjoncology.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 6BTOG 2024 insights & future directions: a comprehensive approach to thoracic malignancies - 24 day(s) ago
Sanjay Popat, from The Royal Marsden NHS Foundation Trust in London, UK, shares his enthusiasm for the BTOG 2024 congress in Belfast, UK, which gathered over a thousand delegates. The meeting emphasized the comprehensive approach to managing primary thoracic malignancies, with representation from various disciplines including respiratory physicians, medical oncologists, surgeons, and more. Prof. Popat highlights BTOG’s commitment to providing equitable and optimal care through education, research, facilitation, and representation. He encourages registration for membership, offering access to CPD accredited educational materials and specialist events. The upcoming agenda includes webinars updating on international meetings outcomes and essential updates on mesothelioma and stage IV malignancies treatment paradigms. Notably, BTOG introduces a research group to foster structured academic drug trials research. Prof. Popat looks forward to reconvening at BTOG 2025 for another enriching meet
Source: www.vjoncology.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0VJOncology – The video journal of oncology - 24 day(s) ago
The Video Journal of Oncology (VJOncology) is an independent, global, open-access video journal, dedicated to providing trusted and up-to-date information in order to improve the awareness and understanding of oncology
Source: www.vjoncology.comCategories: General Medicine News, Onc News and JournalsTweet
🎥@drenriquegrande of @MDAnderson_ES discusses practice-changing findings from EV-302 trial on enfortumab vedotin and pembrolizumab in advanced urothelial cancer: ➡️https://t.co/sgJylc3Soi⬅️ #ESMOAsia23 #ImmunoOnc #CTSM #UroOnc #UroSoMe #BlcSM